Professor of Neurology, Harvard Medical School; and Translational Neurology Head of the Interdisciplinary Brain Center, Massachusetts General Hospital
“Assessing long-term stability of cerebrospinal fluid PrP levels in genetic prion disease mutation carriers”
Laboratory of Prion Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
“Nanoparticle-mediated brain delivery of a tetracationic porphyrin with potent anti-prion activities”
National Institute of Allergy and Infectious Diseases, NIH
“Cerebral neuronal dysfunction associated with human prion diseases”
Medical Research Council (MRC) Prion Unit at University College London
“Development of a quantitative, real-time Protein-Misfolding by Cyclic Amplification (PMCA) reaction”
Professor, Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI
“Determining the therapeutic potential of anti-PrP nanobody”
Center for Regenerative Medicine, Boston University School of Medicine
“Modeling Creutzfeldt-Jakob Disease Using Human iPSC-derived Neurons”
Medical Research Council (MRC) Prion Unit at University College London
“Investigating the relevance of blood DNA methylation signals for disease management in CJD”
Institute of Neuropathology, University Medical Center – Eppendorf, Hamburg, Germany
“Investigating the Potential of the Neuroprotective N1 Fragment of the Prion Protein as a New Treatment Against Prion Diseases”
Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada
“Isolation and Strain-Specific Characterization of Pathogenic CJD Prion Particles”
Department of Biochemistry, Boston University School of Medicine
“Highly Synergistic Combination Therapy for Prion Diseases”
Rocky Mountain Laboratories, Montana
“Investigation of Prion Inactivation by Reactive Oxygen Species in Vivo”
Institute for Regenerative Medicine and Biotherapy, University of Montpellier, France
“Innovative Human 3D Neural Network Model for the Efficient Propagation of Human Prions”
Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, University of Texas-Houston Medical School
“Systematic Evaluation of the Zoonotic Potential of Different CWD Isolates”
Alzheimer's and Prion diseases Lab. at the Brain & Spine Institute (ICM) of the Salpêtrière Hospital, Sorbonne Université, Paris, France
Worms: A novel genetic model for therapeutic research in prion disease
Mitchell Center for Alzheimer’s Disease and Related Brain Disorders, Department of Neurology, University of Texas-Houston Medical School
Design and Development of Anti-Prions as a Novel Therapeutic Strategy for Prion Disease
University of Verona, Italy
RT-QuIC assay on olfactory brushings in asymptomatic carriers of E200K mutation: An explorative study for establishing when a preventive therapy should be started
National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, Ohio
Assessing Prions in Sporadic CJD Patients
Institute of Neuropathology, University Medical Center Eppendorf
Targeting the endogenous proteolytic processing of PrPc as a therapeutic strategy against prion diseases
National Institute of Allergy and Infectious Diseases, National Institute of Health
Antisense Oligonucleotides to delay or prevent onset of prion disease in mice
Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
A new anti-prion compound that reduces PrPc levels and inhibits PrPsc replication. [Awaiting permission to release from Dr. Chiesa.]
